Dr. Jennifer Richer, Professor of Pathology, University of Colorado Anschutz Medical Campus, has over 23 years of experience and an international reputation in the field of nuclear hormone receptor action. Her laboratory tackles clinically relevant issues related to hormone dependent women’s cancers. Recent work demonstrated a role for the androgen receptor (AR) in preclinical models of estrogen receptor (ER) positive, HER2+, and triple negative breast cancer, leading to a Department of Defense Breast Cancer Research Program Clinical Translational Grant to investigate targeting AR in breast cancer. Another major focus is identifying non-coding RNA that affect hormone receptor action and progression of breast and ovarian cancer. Dr. Richer has >65 publications, was a co-organizer of Keystone Symposium on Nuclear Receptors in 2016 and serves as associate editor of Hormones and Cancer and editorial board of Breast Cancer Research. She has served on scientific advisory boards for MD Anderson Uterine Cancer SPORE, Medivation, Bayer, Innocrin, and Orion Pharma. She is a standing member of the NIH Tumor Cell Biology Study Section. Dr. Richer is very involved in cancer biology graduate education and won the University of Colorado Graduate School Mentoring Award and NIH Broadening Experiences in Scientific Training (BEST) Faculty Sponsor Award in 2015/16.
Abstracts this author is presenting: